1
|
Zhu W, Chen H, Jia H, Chai Y, Yang J, Wang Z, Wu H. Long-Term Hearing Preservation Outcomes for Small Vestibular Schwannomas: Retrosigmoid Removal Versus Observation. Otol Neurotol 2019; 39:e158-e165. [PMID: 29315192 DOI: 10.1097/mao.0000000000001684] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Management of small vestibular schwannomas (VSs) consists of three options: serial observation, radiosurgery, and microsurgery. The authors reported the long-term hearing outcomes after retrosigmoid tumor removal in 110 patients and hearing follow-up outcomes in 160 serial observation patients with small VSs to explore the appropriate management strategy and predictive factors of hearing preservation for small VSs. STUDY DESIGN Retrospective study. SETTING Tertiary referral center. PATIENTS In this study, 110 patients with small VS (purely intracanalicular/cerebellopontine angle tumor ≤15 mm) during a 15-year period, from January 2001 to December 2015, were candidates for hearing preservation surgery through retrosigmoid approach, while 160 patients were candidates for serial observation. The main outcome measure was preservation of hearing under different hearing levels, assessed with the classification of American Academy of Otolaryngology-Head and Neck Surgery. RESULTS Preoperative hearing levels of the 110 study patients were Class A in 49 patients, Class B in 43 patients, and Class C in 18 patients. In all surgery patients (n = 110), 97.3% (107/110) patients maintained the same level during postoperative follow-up (mean follow-up time was 49.1 ± 28.2 mo) and 86 (78.2%) had complete radiologic and audiometric data at least 4 years follow-up for review. In the 4 years follow-up surgery group (n = 86), postoperative hearing levels were Class A, B, C, and D for 22, 11, 18, and 35 patients, and postoperative rates of preservation of serviceable and useful hearing were 59.3% (51/86) and 47.1% (33/70), respectively. In serial observation group, mean follow-up time was 35.2 ± 33.1 months; mean tumor size at presentation was 8.6 ± 4.3 mm; overall mean tumor growth rate was 1.08 ± 2.3 mm/yr; serviceable hearing preservation rate of 98 patients was 54.1% (53/98) at the 5-year end point and 48.7% (37/76) at the 7-year end point. CONCLUSION Tumor removal should be the first treatment option for patients with small VSs and preserved hearing, especially for young patients with good hearing; retrosigmoid approach is an effective and safe approach for small VSs removal with excellent functional outcomes; better preoperative hearing predicted a higher rate of postoperative hearing preservation; patients without fundal extension were more likely to achieve hearing preservation than those with fundal extension, but no difference had been detected when retrosigmoid removal assisted with endoscope was performed; patients with small tumors originating from SVN were more likely to achieve hearing preservation compared with those with IVN-originating tumors.
Collapse
Affiliation(s)
- Weidong Zhu
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Hongsai Chen
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Huan Jia
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Yongchuan Chai
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Jie Yang
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Zhaoyan Wang
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - Hao Wu
- Department of Otolaryngology Head and Neck Surgery, Ninth People's Hospital.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases.,Ear Institute, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| |
Collapse
|
2
|
Puataweepong P, Dhanachai M, Dangprasert S, Narkwong L, Sitathanee C, Sawangsilpa T, Janwityanujit T, Yongvithisatid P. Linac-based stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannomas: comparative observations of 139 patients treated at a single institution. JOURNAL OF RADIATION RESEARCH 2014; 55:351-8. [PMID: 24142966 PMCID: PMC3951083 DOI: 10.1093/jrr/rrt121] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/19/2013] [Revised: 09/15/2013] [Accepted: 09/19/2013] [Indexed: 06/02/2023]
Abstract
Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) have been recognized as an alternative to surgery for small to medium sized vestibular schwannoma (VS). This study analysed and compared the outcomes of VS treated with the first Thailand installation of a dedicated Linac-based stereotactic radiation machine using single-fraction radiosurgery (SRS), hypofraction stereotactic radiotherapy (HSRT) and conventional fraction stereotactic radiotherapy (CSRT). From 1997 to 2010, a total of 139 consecutive patients with 146 lesions of VS were treated with X-Knife at Ramathibodi hospital, Bangkok, Thailand. SRS was selected for 39 lesions (in patients with small tumors ≤3 cm and non-serviceable hearing function), whereas HSRT (79 lesions) and CSRT (28 lesions) were given for the remaining lesions that were not suitable for SRS. With a median follow-up time of 61 months (range, 12-143), the 5-year local control rate was 95, 100 and 95% in the SRS, HSRT and CSRT groups, respectively. Hearing preservation was observed after SRS in 75%, after HSRT in 87% and after CSRT in 63% of the patients. Cranial nerve complications were low in all groups. There were no statistically significant differences in local control, hearing preservation or complication between the treatment schedules. In view of our results, it may be preferable to use HSRT over CSRT for patients with serviceable hearing because of the shorter duration of treatment.
Collapse
Affiliation(s)
- Putipun Puataweepong
- Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Mahidol University, Bangkok, 10400, Thailand
| | - Mantana Dhanachai
- Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Mahidol University, Bangkok, 10400, Thailand
| | - Somjai Dangprasert
- Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Mahidol University, Bangkok, 10400, Thailand
| | - Ladawan Narkwong
- Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Mahidol University, Bangkok, 10400, Thailand
| | - Chomporn Sitathanee
- Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Mahidol University, Bangkok, 10400, Thailand
| | - Thiti Sawangsilpa
- Radiation and Oncology Unit, Department of Radiology, Faculty of Medicine, Mahidol University, Bangkok, 10400, Thailand
| | - Taweesak Janwityanujit
- Radiosurgery Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand
| | - Pornpan Yongvithisatid
- Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand
| |
Collapse
|
3
|
Kondziolka D, Mousavi SH, Kano H, Flickinger JC, Lunsford LD. The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation? Neurosurg Focus 2013; 33:E8. [PMID: 22937859 DOI: 10.3171/2012.6.focus12192] [Citation(s) in RCA: 105] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT Management recommendations for patients with smaller-volume or newly diagnosed vestibular schwannomas (< 4 cm(3)) need to be based on an understanding of the anticipated natural history of the tumor and the side effects it produces. The natural history can then be compared with the risks and benefits of therapeutic intervention using a minimally invasive strategy such as stereotactic radiosurgery (SRS). METHODS The authors reviewed the emerging literature stemming from recent recommendations to "wait and scan" (observation) and compared this strategy with published outcomes after early intervention using SRS or results from matched cohort studies of resection and SRS. RESULTS Various retrospective studies indicate that vestibular schwannomas grow at a rate of 0-3.9 mm per year and double in volume between 1.65 and 4.4 years. Stereotactic radiosurgery arrests growth in up to 98% of patients when studied at intervals of 10-15 years. Most patients who select "wait and scan" note gradually decreasing hearing function leading to the loss of useful hearing by 5 years. In contrast, current studies indicate that 3-5 years after Gamma Knife surgery, 61%-80% of patients maintain useful hearing (speech discrimination score > 50%, pure tone average < 50). CONCLUSIONS Based on published data on both volume and hearing preservation for both strategies, the authors devised a management recommendation for patients with small vestibular schwannomas. When resection is not chosen by the patient, the authors believe that early SRS intervention, in contrast to observation, results in long-term tumor control and improved rates of hearing preservation.
Collapse
Affiliation(s)
- Douglas Kondziolka
- The Center for Image Guided Neurosurgery, UPMC, Pittsburgh, Pennsylvania, USA.
| | | | | | | | | |
Collapse
|
4
|
Maier W, Grauvogel T, Laszig R, Ridder G. Wertigkeit unterschiedlicher Methoden zur Behandlung von Akustikusneurinomen. HNO 2011; 59:425-36. [DOI: 10.1007/s00106-011-2302-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Sakanaka K, Mizowaki T, Arakawa Y, Araki N, Oya N, Takahashi JA, Mikuni N, Miyamoto S, Hashimoto N, Hiraoka M. Hypofractionated stereotactic radiotherapy for acoustic neuromas: safety and effectiveness over 8 years of experience. Int J Clin Oncol 2010; 16:27-32. [PMID: 20830603 DOI: 10.1007/s10147-010-0122-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Accepted: 08/08/2010] [Indexed: 10/19/2022]
Abstract
BACKGROUND Little information is available about long-term outcomes of hypofractionated stereotactic radiotherapy (hypo-FSRT) for acoustic neuromas. In this study, the safety and effectiveness of hypo-FSRT for unilateral acoustic neuroma were reviewed over 8 years of experience at our institution. METHODS Between May 1998 and October 2006, 27 patients were consecutively treated by linear accelerator-based hypo-FSRT. Two patients were excluded from this study because they were lost to follow-up within 12 months. The median follow-up period for the rest was 59 (range 24-133) months. Two types of treatment schedules were adopted. Thirteen patients received 30-39 Gy, given in 10-13 fractions (regimen A), whereas after July 2003, 12 patients received 20-24 Gy, given in 5-6 fractions at the tumor periphery (regimen B). These treatments were scheduled to be delivered in three fractions per week (Monday, Wednesday, Friday). The median planning target volume was 2.0, with 1.7 ml (range 0.7-10.6) in regimen A and 5.2 ml (range 0.9-9.3) in regimen B. In the pretreatment audiogram, seven patients (two in regimen A and five in regimen B) had serviceable hearing (Gardner-Robertson Class I-II). RESULTS Local control rates were 100% with regimen A and 92% with regimen B. Serviceable hearing was preserved in four of five patients in regimen B but no patients in regimen A at the last follow-up. No permanent facial or trigeminal nerve morbidity was observed following treatment, and no salvage surgery was needed. CONCLUSIONS Hypo-FSRT for acoustic neuromas achieved a high local control rate with minimal facial and trigeminal nerve morbidity.
Collapse
Affiliation(s)
- Katsuyuki Sakanaka
- Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, 54 Sho-goin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Morrison D. Management of patients with acoustic neuromas: a Markov decision analysis. Laryngoscope 2010; 120:783-90. [PMID: 20213657 DOI: 10.1002/lary.20819] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVES/HYPOTHESIS The management of patients with small (<1.5 cm) acoustic neuromas is controversial. Immediate treatment via microsurgical resection or radiosurgery is often advocated. A period of observation is sometimes advised followed by microsurgery or radiosurgery for tumors that demonstrate growth during the observation period. The purpose of this study is to calculate quality-adjusted life expectancy for the most commonly applied management strategies in hypothetical cohorts of patients of various ages. STUDY DESIGN Markov decision analysis; societal perspective. METHODS Assumptions used in creating this model and event probabilities were obtained from a thorough literature review. Key parameters were identified and defined by the best available evidence. The main outcome measure is the benefit derived from each management strategy in quality-adjusted life years (QALYs). Sensitivity analysis was used to define benchmark performance information for these parameters. RESULTS The benefit of a period of observation followed by radiosurgery, if needed, for significant tumor growth is greater then all other strategies for all age groups and both sexes. When compared to observation followed by microsurgery, the additional benefit is small. QALY totals for the two immediate treatment groups were significantly lower than that for the observation groups. CONCLUSIONS For patients of all ages, a period of observation during which tumor growth and hearing thresholds are closely monitored is the superior strategy. For tumors that grow substantially or when hearing deteriorates, definitive management via radiosurgery is recommended.
Collapse
Affiliation(s)
- Daniel Morrison
- Section of Otolaryngology, Dartmouth Medical School, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA.
| |
Collapse
|
7
|
Bhandare N, Mendenhall WM, Antonelli PJ. Radiation Effects on the Auditory and Vestibular Systems. Otolaryngol Clin North Am 2009; 42:623-34. [DOI: 10.1016/j.otc.2009.04.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Plotkin SR, Halpin C, Blakeley JO, Slattery WH, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009; 93:61-77. [PMID: 19430883 DOI: 10.1007/s11060-009-9867-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2008] [Accepted: 03/16/2009] [Indexed: 01/31/2023]
Abstract
Neurofibromatosis type 2 (NF2) is a tumor suppressor gene syndrome characterized by multiple schwannomas, especially vestibular schwannomas (VS), and meningiomas. Anticancer drug trials are now being explored, but there are no standardized endpoints in NF2. We review the challenges of NF2 clinical trials and suggest possible response criteria for use in initial phase II studies. We suggest two main response criteria in such trials. Objective radiographic response is defined as a durable 20% or greater reduction in VS volume based on post-contrast T1-weighted MRI images collected with 3 mm or finer cuts through the internal auditory canal. Hearing response is defined as a statistically significant improvement in word recognition scores using 50-word recorded lists in audiology. A possible composite endpoint incorporating both radiographic response and hearing response is outlined. We emphasize pitfalls in response assessment and suggest guidelines to minimize misinterpretations of response. We also identify research goals in NF2 to facilitate future trial conduct, such as identifying the expectations for time to tumor progression and time to measurable hearing loss in untreated NF2-related VS, and the relation of both endpoints to patient prognostic factors (such as age, baseline tumor volume, and measures of disease severity). These data would facilitate future use of endpoints based on stability of tumor size and hearing, which might be more appropriate for testing certain drugs. We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents.
Collapse
Affiliation(s)
- Scott R Plotkin
- Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
McClelland S, Gerbi BJ, Higgins PD, Orner JB, Hall WA. Safety and efficacy of fractionated stereotactic radiotherapy for acoustic neuromas. J Neurooncol 2007; 86:191-4. [PMID: 17622486 DOI: 10.1007/s11060-007-9456-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2007] [Accepted: 06/25/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND The treatment of acoustic neuromas (AN) has historically involved surgical excision or stereotactic radiosurgery, with a relatively limited number of reports available describing the use of fractionated stereotactic radiotherapy (FSRT). To enhance the existing knowledge regarding the safety and efficacy of this treatment modality, we describe our initial experience with FSRT for AN. METHODS From 1999-2005, 20 patients (12F, 8M) with AN underwent FSRT. All patients were treated using the Radionics X-Knife 4.0 3D planning system, receiving 54 Gy in 1.8 Gy daily fractions with a prescription isodose line of 90%. Treatments were delivered stereotactically using a dedicated Varian 6/100 linear accelerator, with immobilization achieved via the Gill-Thomas-Cosman relocatable frame. Median tumor size (maximum diameter) was 2.1 cm (range, 1.1-3.4 cm). Median patient age was 49.5 years, with median follow-up of 22 months (range, 1-66 months). All patients were evaluated with pre- and post-gadolinium-enhanced magnetic resonance imaging. RESULTS Following FSRT, local tumor control was achieved in every patient, with the treatment well-tolerated by all patients. No patient experienced acute complications or facial nerve weakness. Two patients experienced permanent trigeminal nerve morbidity manifesting as facial numbness. All nine patients with preserved hearing before treatment had hearing preservation at last follow-up, although four of these patients experienced hearing decline following FSRT. CONCLUSION In our series of 20 patients with AN, all had local tumor control following FSRT, with minimal morbidity. These results support the growing body of literature demonstrating the safety and efficacy of FSRT in achieving local control for AN, further validating the viability of FSRT as a treatment modality for this patient population.
Collapse
Affiliation(s)
- Shearwood McClelland
- Department of Neurosurgery, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
| | | | | | | | | |
Collapse
|
10
|
Rutten I, Baumert BG, Seidel L, Kotolenko S, Collignon J, Kaschten B, Albert A, Martin D, Deneufbourg JM, Demanez JP, Stevenaert A. Long-term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma. Radiother Oncol 2007; 82:83-9. [PMID: 17182142 DOI: 10.1016/j.radonc.2006.11.019] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2006] [Revised: 11/17/2006] [Accepted: 11/22/2006] [Indexed: 11/21/2022]
Abstract
AIM The long-term effects of radiosurgery of vestibular schwannomas were investigated in a group of consecutively treated patients. METHODS AND MATERIALS Between 1995 and 2001, 26 patients (median age: 67, range: 30-82) with a vestibular schwannoma were treated by Linac-based stereotactic radiosurgery (SRS). The median follow-up was 49 months (16-85 months). Only progressive tumours were treated. The median size of tumours was 18 mm (range 9-30 mm). Before SRS, 11 patients had a useful hearing (Gardner-Robertson classes 1 and 2). Single doses of 10-14 Gy were prescribed at the 80% isodose at the tumour margin. The follow-up consisted of regular imaging with MRI the first 3-6 months after the intervention, followed by additional yearly MRIs, a hearing test and a neurological examination. RESULT The 5-year-probability of tumour control (defined as stabilization or decrease in size) was 95%. Five-year-probability of preservation of hearing and facial nerve function was 96% and 100%, respectively. Hearing was preserved in 10 out of 11 patients who had a normal or useful hearing at the time of treatment. Mild and transient trigeminal toxicity occurred in 2 (8%) patients. It appeared to be significantly correlated to the dose used (p=0.044). However, only a tendency to significance could be demonstrated in the relationship between the two factors when using the Cox analysis (hazard ratio=1.7; 95% CI: 0.7-3.9; p=0.23). CONCLUSIONS With the doses used, our study demonstrates that SRS provides an equivalent tumour control rate when compared to surgery, as well as on a long-term basis, an excellent preservation of the facial and the acoustic nerves. Although no permanent trigeminal toxicity was observed, our data confirm that doses below 14 Gy can avoid transient dysesthesias.
Collapse
Affiliation(s)
- Isabelle Rutten
- Department of Radiotherapy, C.H.U. of Liège, Liège, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Flickinger JC, Barker FG. Clinical Results: Radiosurgery and Radiotherapy of Cranial Nerve Schwannomas. Neurosurg Clin N Am 2006; 17:121-8, vi. [PMID: 16793504 DOI: 10.1016/j.nec.2006.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Stereotactic radiosurgery and fractionated radiotherapy are two attractive low-morbidity alternatives to surgical resection for managing cranial nerve schwannomas. Treatment outcomes from these radiation treatment approaches are well documented with long-term outcome studies from multiple institutions. Differences in outcome between these two modalities are difficult to define clearly. The low morbidity and high long-term tumor control rates with radiation treatment have made it the choice of many patients who opt for active initial management for small- or medium-sized cranial nerve schwannomas.
Collapse
Affiliation(s)
- John C Flickinger
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
| | | |
Collapse
|
12
|
Chung HT, Ma R, Toyota B, Clark B, Robar J, McKenzie M. Audiologic and treatment outcomes after linear accelerator–based stereotactic irradiation for acoustic neuroma. Int J Radiat Oncol Biol Phys 2004; 59:1116-21. [PMID: 15234046 DOI: 10.1016/j.ijrobp.2003.12.032] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2003] [Revised: 12/16/2003] [Accepted: 12/19/2003] [Indexed: 11/15/2022]
Abstract
PURPOSE Although surgical excision is the traditional treatment modality for acoustic neuroma, radiotherapy (RT) is gaining momentum as an alternative. This is particularly evident in patients with useful hearing, in whom fractionated RT offers the potential for hearing preservation. Our objective was to determine the disease control, hearing preservation (via audiograms), and toxicity rates after linear accelerator-based stereotactic radiation for acoustic neuroma. METHODS AND MATERIALS A total of 72 acoustic neuroma patients underwent stereotactic irradiation and had at least 6 months of follow-up between October 1997 and March 2002. Of these, 45 received single-fraction stereotactic radiosurgery (SRS) and 27 received fractionated stereotactic radiotherapy (SRT). Before treatment, all SRS patients were functionally deaf and 23 of 25 SRT patients had useful hearing in the affected ear. The minimal peripheral dose was 12 Gy and 45 Gy in all SRS and SRT patients, respectively. Tumor control, toxicity, and hearing preservation were recorded. RESULTS The median follow-up in the SRS and SRT groups was 27 and 26 months, respectively. No tumor progression was seen after SRS and SRT. On the basis of the audiogram criteria, the 1-year and 2-year hearing preservation rate was 85% and 57%, respectively. The mean pre- and post-SRT speech recognition threshold was 20 and 38 dB, respectively. The mean proportion of pre- and post-SRT speech discrimination was 91% and 59%, respectively. CONCLUSION Stereotactic RT achieves good local control, with acceptable toxicity. RT fractionation appears to provide encouraging rates of hearing preservation.
Collapse
Affiliation(s)
- Hans T Chung
- Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
| | | | | | | | | | | |
Collapse
|
13
|
Tonn JC. Microneurosurgery and radiosurgery--an attractive combination. ACTA NEUROCHIRURGICA. SUPPLEMENT 2004; 91:103-8. [PMID: 15707031 DOI: 10.1007/978-3-7091-0583-2_11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Microneurosurgery and radiosurgery have made tremendous progress in terms of increasing efficacy and reducing treatment related mobility. Both techniques have clear indications; however, there is still competition between the two modalities in a variety of diseases. In all instances, this rivalry should be replaced by the concept of using both methods as complementary. Skull base tumours, metastases as well as certain AVMs are good candidates for this approach.
Collapse
Affiliation(s)
- J C Tonn
- Department of Neurosurgery, Maximilians University, Munich, Germany.
| |
Collapse
|
14
|
Abstract
PURPOSE To discuss the optimal management for patients with acoustic schwannoma. MATERIALS AND METHODS Review of the pertinent literature. RESULTS Microsurgery, stereotactic radiosurgery, and fractionated radiotherapy result in cure rates that approximate 90% at 5 years. Depending on tumor extent and surgical approach, the morbidity of microsurgery may exceed that of stereotactic radiosurgery and fractionated radiotherapy. Patients with useful hearing before treatment may have a higher likelihood of hearing preservation after radiotherapy compared with radiosurgery. CONCLUSION Both microsurgery and radiosurgery are good options for patients with tumors less than 3 cm. Depending on tumor extent and the surgical approach, the morbidity of microsurgery may exceed that of radiosurgery. Patients with useful hearing may have a higher likelihood of hearing preservation after radiotherapy. Microsurgery is preferred for patients in whom the disease progresses after initial irradiation and in patients with tumors larger than 3 cm.
Collapse
Affiliation(s)
- William M Mendenhall
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, 32610-0385, USA.
| | | | | | | |
Collapse
|
15
|
Abstract
Despite their particular functional consequences, radiotherapy-induced ear injuries remain under-evaluated and under-reported. These reactions may have acute or late character, may affect all structures of the hearing organ, and result in conductive, sensorineural or mixed hearing loss. Up to 40% of patients have acute middle ear side effects during radical irradiation including acoustic structures and about one-third of patients develop late sensorineural hearing loss (SNHL). Total radiotherapy dose and tumour site seem to be among the most important factors associated with the risk of hearing impairment. Thus, reduction in radiation dose to the auditory structures should be attempted whenever possible. New radiotherapy techniques (3-dimensional conformal irradiation, intensity modulated radiotherapy, proton therapy) allow better dose distribution with lower dose to the non-target organs. Treatment of acute and late external otitis is mainly conservative and includes the anti-inflammatory agents (applied topically and systematically). Post-radiation chronic otitis media and the eustachian tube pathology may be managed with tympanic membrane incision with insertion of a tympanostomy tube (grommet), although the benefit of such approach is controversial and some authors advocate a more conservative approach. In these patients the functional deficit can be alleviated by application of bone conduction hearing aids such as, e.g., the bone anchored hearing aid (BAHA). There is no standard therapy for post-irradiation sudden or progressive SNHL yet corticosteroid therapy, rheologic medications, hyperbaric oxygen or carbogen therapy are usually employed (as for idiopathic SNHL), although controversial data on the efficacy of these treatment modalities have been published. In selected cases with bilateral profound hearing loss or total deafness, cochlear implants may prove effective. Further improvements in radiotherapy techniques and progress in otologic diagnostics and therapy may allow better prevention and management of radiation-related acoustic injury.
Collapse
Affiliation(s)
- Barbara A Jereczek-Fossa
- Division of Radiation Oncology of the European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.
| | | | | | | |
Collapse
|
16
|
Horstmann GA, Van Eck ATCJ. Gamma knife model C with the automatic positioning system and its impact on the treatment of vestibular schwannomas. J Neurosurg 2002. [DOI: 10.3171/jns.2002.97.supplement_5.0450] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object. The aim of this study was to assess the effects of the gamma knife automatic positioning system (APS) on the treatment of patients, particularly effects of this system on the treatment of patients with vestibular schwannomas (VSs), with a view to reducing loss of hearing.
Methods. The dose delivery with an increased number of shots was checked with GAFChromic Film for various numbers of shots (one to 129). The results in the first 549 patients were recorded. In addition a series of 59 patients with VSs treated with 13 Gy to the 65% isodose is presented. The authors have termed this the “13 on 65” concept.
The film dosimetry showed that a large number of small shots did not materially affect the dose and dose distribution produced by gamma knife treatment.
The APS was used alone in 72% of arteriovenous malformations, 71% of meningiomas, 94% of VSs, and 84% of pituitary adenomas. Metastatic tumors were accessible in a pure APS mode in 59% of all cases, glioma in 58%, and uveal melanoma in 10% of the cases. Thus two thirds of patients could be treated using APS alone. It was possible to use the APS and manual systems together for complex or very eccentrically placed targets. The APS resulted in the use of a larger number of isocenters.
After a mean follow-up period of 15 months, the results in patients with the VSs in whom 13 Gy was delivered to the 65% isodose were similar to those in patients treated with the more conventional 50% margin isodose. There was no change in the incidence of hearing loss within the study period, and the incidence of trigeminal and facial neuropathies remained unchanged after treatment as well.
Conclusions. The APS encourages the design of more conformal dose plans. The greater use of smaller collimators results in a steeper dose gradient with a smaller amount of radiation outside the target volume. Because the APS is able to apply a large number of smaller isocenters in an acceptable time, the number of isocenters used is increased. An increased number of isocenters can also be used to reduce the maximum radiation dose and increase the homogeneity in a given dose plan.
Collapse
|